PRECLINICAL CANCER OF THE
A glioma is a cancer type that involves the glial cell in the brain or spine and accounts for approximately 30% of all brain tumors. Gliomas can be especially aggressive, explaining why they account for 80% of all malignant brain tumors. Since many therapies are initially developed in preclinical animal models, noninvasive approaches facilitate the study of tumor growth and the molecular profile of the tumor. PET and optical imaging are commonly used for molecular imaging, but have the respective drawbacks of requiring the use of radioisotopes or suffering from photon scatter. MSOT has been used to bridge the gap between the limitations of the use of radioactive contrast agents and poor optical spatial resolution to provide noninvasive, high-resolution imaging of the brain with contrast agents that are easily synthesized and handled. It has also been used as a low-cost alternative to BOLD MRI imaging to study the hemodynamics of brain tumors.